Billions of blood products industry, these enterprises deserve attention.

Pharmaceutical Network Industry Dynamics Is well known, with high technology, high input and other characteristics of blood products clinical value is very high, coupled with the state supervision, its technical barriers are higher, undoubtedly belong to the excellent trackand according to the data, China's blood products industry as a whole market size of about 32 billion, if excluding imported albumin, the current domestic blood products enterprise market size of about 20 billiontherefore, comprehensive from the perspective of industry development, the future in the positive policy and extension of mergers and acquisitions and other factors, the concentration of the blood products industry will be greatly increased, and its investment value will be increased simultaneouslyin this context, the industry suggests that you can pay attention to the Temple of Heaven biology, Hualan biology, Shanghai Leishi and other leading enterprises, their advantages are mainly in the number of pulp stations, pulp volume, varieties and batch issuance dataTiantan Bio-Tiantan Biological Sesame is listed as a biological products company under the shares of Zhongsheng, the main vaccine and blood products business, after a major asset restructuring, Tiantan Bio stripped all vaccine products, placed in wusheng, Lansheng, shengand and Guizhou blood productsat present, the company in research and product strains including albumin, immunoglobulin, coagulation factors and other blood productsaccording to the 2019 batch issuance data show that the Tiantan biological human haemoglobin batch issued about 433.07 million bottles, an increase of 23% yoY, accounting for about 20% of domestic albumin; The number of free-to-approve issues of 1.3887 million bottles, up 179% YoY, accounting for about 22% of the industry;, according to Tiantan Bio's 2019 full-year results forecast, it has achieved the collection of 1706 tons of plasma in 2019, an increase of 8.8% year-on-yearand by increasing product yield, controlling production costs, strengthening market sales, its product margin has also increased significantlyHualan Biological Hualan Biological was founded in 1992, the main business is engaged in research and development and production of blood products, is a leading enterprise in blood productsmain products include human haemoglobin, static injection of human immunoglobulin (PH4), human coagulation enzyme complex, human coagulation factor VIIIin addition, its total of 26 single plasma collection stations, including 4 in Guangxi, Guizhou 1, Chongqing 16 (including 6 single plasma stationsub-stations), Henan 5;at present, Hualan biological production scale, market share are in the forefront of the industry, has become a blood products, vaccine products industry leading enterprisesShanghai Laith Shanghai Leith's main business for the production and sale of blood products, the main products for human haemoglobin, static injection of human immunoglobulin, specific immunoglobulin, coagulation factor products, etc., is currently one of the large-scale domestic blood products production enterprisesAccording to public information, in 2019 Shanghai Laishi actively promote the pace of the construction of existing plasma stations, accelerate the layout of new single-harvest plasma stationsas of the end of 2019, Shanghai Laishi and its subsidiaries and Sun company has 41 single-harvesting plasma stations (including 1 sub-station), the scope of pulping covers Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi, Shandong 11 provinces (autonomous regions), the company's annual pulp production capacity of nearly 1230 tons, the number of pulp stations, distribution and the region of the best in the industry in addition, from the quarterly report, Shanghai Laith market layout and brand advantages of the growth momentum is being rapidly replicated .